← back to search

Yingqian A. Zhan

University of Idaho · US
Area of research
Oncology · Molecular Biology
Research interest
Research focused on Cancer research and Adenocarcinoma, with related work in Computational biology, Chromatin, Blockade. Notable publications include 'WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC', 'Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation', and 'HiC-DC+ enables systematic 3D interaction calls and differential analysis for Hi-C and HiChIP'.
h-index
citations
543
works
16
NIH funding
primary concept
email

Recent publications

Ageing limits stemness and tumorigenesis by reprogramming iron homeostasis
Nature 2024cited by 57position: middledoi
ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer
Science Advances 2024cited by 39position: middledoi
SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing
Journal of Hematology & Oncology 2024cited by 32position: middledoi
CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation
Signal Transduction and Targeted Therapy 2024cited by 23position: middledoi
ChromaFold predicts the 3D contact map from single-cell chromatin accessibility
Nature Communications 2024cited by 19position: middledoi
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers
Science Translational Medicine 2023cited by 44position: middledoi
WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC
Cell Reports 2022cited by 129position: middledoi
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation
Journal of Hematology & Oncology 2021cited by 92position: middledoi
HiC-DC+ enables systematic 3D interaction calls and differential analysis for Hi-C and HiChIP
Nature Communications 2021cited by 62position: middledoi
Intrinsically Disordered Proteins: Controlled Chaos or Random Walk
International Journal of Plant Biology 2016cited by 1position: middledoi
The cis conformation of proline leads to weaker binding of a p53 peptide to MDM2 compared to trans
Archives of Biochemistry and Biophysics 2015cited by 16position: firstdoi
The Effect of Proline CIS Trans Isomerization on P53 MDM2 Binding
Biophysical Journal 2014cited by 0position: firstdoi
Impact of the K24N mutation on the transactivation domain of p53 and its binding to murine double-minute clone 2
Proteins Structure Function and Bioinformatics 2013cited by 21position: firstdoi
The effects of nanoscale geometry and spillover on room temperature storage of hydrogen on silica nanosprings
Journal of Physics D Applied Physics 2013cited by 8position: middledoi
Absolute Binding Affinity Calculation for MDM2 Bound to a Disordered Fragment of P53
Biophysical Journal 2013cited by 0position: firstdoi
Impact of K24N Mutation on p53TAD and its Interaction with MDM2
Biophysical Journal 2012cited by 0position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

F. Marty Ytreberg · University of Idaho6 papers (2012–2015)Elisa de Stanchina · European Molecular Biology Laboratory4 papers (2022–2024)Charles M. Rudin · New York Proton Center4 papers (2022–2024)Parvathy Manoj · Kamineni Institute of Dental Sciences4 papers (2022–2024)Richard P. Koche · New York Proton Center4 papers (2021–2024)Nisargbhai Shah · Memorial Sloan Kettering Cancer Center3 papers (2022–2024)Àlvaro Quintanal-Villalonga · Research Institute Hospital 12 de Octubre3 papers (2023–2024)Andrew Chow · Merck & Co., Inc., Rahway, NJ, USA (United States)3 papers (2022–2024)Christina S. Leslie · Center for Cancer Research2 papers (2021–2024)Umesh Bhanot · New York Structural Biology Center2 papers (2023–2024)Evelyn M. Nguyen · Dana-Farber Cancer Institute2 papers (2022–2024)Juan Qiu · King University2 papers (2023–2024) · 2 papers (2021–2024) · 2 papers (2023–2024) · 2 papers (2023–2024)Joseph M. Chan · Memorial Sloan Kettering Cancer Center2 papers (2022–2024) · 2 papers (2022–2024)Triparna Sen · University of British Columbia2 papers (2022–2024) · 2 papers (2022–2024)Vidushi Durani · Manhattan Scientifics (United States)2 papers (2023–2024)